Welcome to our dedicated page for Genmab SEC filings (Ticker: GMAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Genmab’s antibody platforms power blockbuster drugs and an expansive oncology pipeline—but their SEC disclosures can stretch past 250 pages and dozens of exhibits. Finding where R&D spend shifts, or spotting when executives file Genmab insider trading Form 4 transactions, is challenging when every quarter brings new clinical data and collaboration milestones.
Stock Titan’s AI solves that problem. Our engine reads each Genmab quarterly earnings report 10-Q filing, highlights royalty streams from Darzalex and Tecvayli, and translates accounting footnotes into plain language. You’ll see
- Real-time alerts the moment a Genmab Form 4 insider transactions real-time record hits EDGAR.
- Concise explanations of 8-K material events—drug approvals, trial pauses, or amended AbbVie contracts—so Genmab 8-K material events explained makes sense in minutes.
- Side-by-side comparisons of cash burn across quarters to support your Genmab earnings report filing analysis.
Wondering about equity grants to management? The DEF 14A Genmab proxy statement executive compensation section is automatically summarised, while our dashboards track Genmab executive stock transactions Form 4 against upcoming catalyst dates. Need the big picture? Our AI creates a one-page brief titled Genmab annual report 10-K simplified so you can understand pipeline risks, patent cliffs, and royalty waterfalls without wading through technical jargon. For new investors asking, “How do I start understanding Genmab SEC documents with AI?”—this page is the starting point.
Genmab A/S filed a Form 6-K as a foreign private issuer to furnish a company announcement related to insider dealing disclosures. The filing incorporates this update by reference into several existing Form S-8 registration statements for the company’s equity compensation plans, meaning the information becomes part of those registration documents. The attached exhibit covers transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons.
Genmab Holding II B.V., a wholly owned subsidiary of Genmab A/S, filed Amendment No. 1 to its tender offer to acquire all outstanding common shares of Merus N.V. (MRUS) for $97.00 in cash per share, less any applicable withholding taxes and without interest.
The parties filed HSR premerger notifications on October 28, 2025. As a result, the required 15‑day waiting period will expire at 11:59 p.m., New York City time, on November 12, 2025, unless withdrawn and refiled, shortened by Early Termination, or extended by a Second Request.
The amendment also updates post‑closing governance plans. If Dr. Lundberg resigns as President and CEO of Merus and Merus US, Inc. following the Closing, Genmab plans for the Merus Board to appoint Dr. Jan G.J. van de Winkel as President and CEO. Genmab and the Purchaser have designated Anthony Pagano, Martine J. van Vugt, Ph.D., and Greg Mueller as non‑executive directors and Dr. van de Winkel as executive director, effective upon Closing and, for the non‑executives, subject to adoption of Governance Resolutions at the EGM or a Subsequent EGM.
Genmab Holding II B.V., a wholly owned subsidiary of Genmab A/S, commenced a cash tender offer to purchase all issued and outstanding common shares of Merus N.V. (MRUS) for $97.00 per share, less any applicable withholding taxes and without interest. The offer is made upon the terms and subject to the conditions set forth in the Offer to Purchase dated October 21, 2025, together with the accompanying Letter of Transmittal.
The filing lists related exhibits, including the Offer to Purchase, Letter of Transmittal, a media release announcing commencement, and a Debt Commitment Letter with Morgan Stanley Senior Funding, Inc. A Transaction Agreement among Genmab, the Purchaser, and Merus is referenced. Shareholders who tender and whose shares are accepted would receive cash consideration of $97.00 per share under the offer terms.
FAQ
What is the current stock price of Genmab (GMAB)?
What is the market cap of Genmab (GMAB)?
